Biotech investors read your deck. They also Google you.
Your website is often the first touchpoint they see after an introduction. In that moment they want clarity and credibility. They want signals that your company is as serious as the science it claims to advance.
Many biotech websites undermine that trust. These hidden red flags make investors question whether your company is ready for their capital.
1. Generic messaging that says nothing
“Revolutionizing medicine.”
“Transforming patient outcomes.”
“Changing the future of healthcare.”
These statements are so vague they could apply to thousands of companies. They don’t differentiate your platform or your pipeline. They say nothing about your vision. For investors, generic messaging raises the suspicion that leadership hasn’t clarified the story, or worse, doesn’t have one.
Case example. Picture an early-stage oncology biotech with a Series B deck that claims it is “changing cancer care forever.” The deck shows a single preclinical candidate. The website repeats the same generic claim with no mechanism of action and no indication focus. It has no competitor comparison either. For investors, that reads as over-hype, under-substance.
Fix. Replace platitudes with a precise thesis. What indication are you addressing? Why does your approach matter now? What makes you hard to copy?
2. Incomplete or outdated pipeline information
Your pipeline is the main part of your investor narrative. If it’s missing or outdated, or you bury it three clicks deep, you’re signaling disorganization or worse, lack of progress.
Case example. Suppose a biotech raises a strong Series A around a promising autoimmune therapy, but the pipeline page on its website still lists “undisclosed targets.” Two years later, investors revisit the site and see the same vague graphics. They assume “nothing moved.”
Fix. Keep your pipeline page current. Label the stage, include targets or indications, and date your last update. Even if progress is incremental, showing the timeline of work builds credibility.
3. Leadership pages without real depth
Investors bet on teams as much as science. A leadership page with only headshots and vague titles is a red flag. If investors can’t assess the caliber of your team at a glance, they’ll assume you’re hiding weaknesses.
Case example. Suppose a gene therapy startup lists a CEO and CSO with headshots but no bios. On LinkedIn, the CEO has three unrelated ventures in retail and crypto. The missing detail on the site forces investors to fill in the blanks, and they will assume the worst.
Fix. Highlight credentials, relevant past successes, and affiliations. Use short, sharp bios that show why this team can execute. Include only active advisors.
4. No evidence of momentum
A silent “News” page or empty “Press” section tells investors nothing is happening. Worse, it suggests a company that isn’t getting traction.
Case example. Suppose a Series A biotech makes progress with IND-enabling studies but goes 18 months without updating its site. The next investor who visits sees a stale press release about a seed round. It creates the impression of stagnation, even if work is happening behind the scenes.
Fix. Post updates even if they’re modest, such as conference presentations, new hires, partnerships, and preclinical milestones. Momentum means visible progress, even without a Phase 3 readout.
5. Bloated, outdated technology
Many biotech sites still run on outdated CMS setups, carry too many plugins, or use legacy templates. Investors notice when your site loads slowly or breaks on mobile. They also notice when it looks five years old. They won’t look at your code. That translates to poor operational discipline.
Case example. Suppose a publicly traded biotech launches a new pipeline candidate and announces it on a website that takes 12 seconds to load on mobile. Investors may not know the cause, whether plugin bloat or a legacy theme. They will still register that this company doesn’t sweat operational details.
Fix. Invest in a clean, scalable site built on modern WordPress blocks or equivalent. The site should be fast and secure. Your team should find it easy to update. Infrastructure is part of the signal.
6. Hard-to-find contact pathways
If reaching you is hard, an investor may not try twice. Buried forms and missing emails give the impression of inaccessibility. So do generic info@ addresses.
Case example. Suppose a biotech’s website has only a “General Inquiries” form with no direct investor contact. A potential investor hesitates to use it, unsure where the message will land. In early-stage fundraising, friction like this can mean a missed conversation that never comes back.
Fix. Put an investor contact email in plain sight. Make sure it goes to someone responsible and responsive. Don’t overcomplicate the funnel. Investors treat easy access as a sign of professionalism.
7. Visuals that don’t match the story
Stock DNA helix backgrounds and vague lab imagery don’t instill confidence. They make your company look like every other biotech startup.
Case example. Suppose a CNS biotech touts a differentiated platform but illustrates it with the same double-helix vector image used by dozens of peers. Investors see sameness where the science should be.
Fix. Use visuals that communicate your science. Pipeline diagrams, mechanism of action illustrations, and investor-ready graphics help reinforce the story. Put your differentiator in a diagram.
Websites are signals
A website can’t close the round, and investors know it. The story they heard in your deck or pitch should match what they find on the site. A clean, credible site shows an operationally strong company that is ready for investors and moving. A sloppy site shows the opposite.
Any of these red flags can turn a warm follow-up into a quiet pass. Trust compounds in biotech, and the website is the first and easiest signal to get right.
